| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
140 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
3 |
| Net Income (TTM) (Millions $) |
-37 |
| Cash Flow (TTM) (Millions $) |
1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Generex Biotechnology Corp is a biopharmaceutical company that focuses on researching, developing, and commercializing drug delivery technologies and products. The company's primary focus is on the development of a proprietary liquid-based formulation for delivering therapeutics through the buccal mucosa or oral cavity. This technology, called buccal drug delivery, provides a non-invasive and convenient delivery mechanism, eliminating the need for injections or pills.
Generex Biotechnology Corp also owns Antigen Express Inc, a subsidiary that develops immunotherapeutic vaccines for the treatment of cancer and other diseases. The company's lead product candidate is AE37, a breast cancer vaccine currently in late-stage clinical trials.
In addition to its drug delivery technologies and vaccines, Generex Biotechnology Corp also owns subsidiaries that focus on the development and commercialization of different medical devices, including a proprietary glucose monitoring system and a rapid COVID-19 antigen test.
Overall, the company aims to improve patient outcomes and provide innovative solutions for drug delivery and disease management through its various technologies and product offerings.
|
%